Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
Public ClinicalTrials.gov record NCT02915016. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA, and of MF59®- or AS01B-Adjuvanted Clade C Env Protein in Various Combinations, in Healthy, HIV-Uninfected Adult Participants
Study identification
- NCT ID
- NCT02915016
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Enrollment
- 334 participants
Conditions and interventions
Conditions
Interventions
- DNA-HIV-PT123 vaccine Biological
- Bivalent Subtype C gp120/MF59 vaccine Biological
- Bivalent Subtype C gp120/AS01B vaccine Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 40 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 6, 2016
- Primary completion
- Aug 6, 2019
- Completion
- Feb 11, 2020
- Last update posted
- Apr 28, 2022
2016 – 2020
United States locations
- U.S. sites
- 8
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama CRS | Birmingham | Alabama | 35294 | — |
| Brigham and Women's Hospital Vaccine CRS (BWH VCRS) | Boston | Massachusetts | 02115-6110 | — |
| Fenway Health (FH) CRS | Boston | Massachusetts | 02215-4302 | — |
| Columbia P&S CRS | New York | New York | 10032-3732 | — |
| New York Blood Center CRS | New York | New York | 10065 | — |
| University of Rochester Vaccines to Prevent HIV Infection CRS | Rochester | New York | 14642 | — |
| Vanderbilt Vaccine (VV) CRS | Nashville | Tennessee | 37232-2582 | — |
| Seattle Vaccine and Prevention CRS | Seattle | Washington | 98109-1024 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02915016, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2022 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02915016 live on ClinicalTrials.gov.